Vmbook Online ordering

Oxigene Inc

Sure, Oxigene Inc. is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol "OXGN". Here are some general information about the company:

Oxigene Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of cancer and other diseases. The company's lead product candidate is OXG-101, which is currently in Phase 3 clinical trials for the treatment of pancreatic cancer.

Oxigene was incorporated in 2017 and is based in South San Francisco, California. The company's mission is to revolutionize cancer treatment by developing therapies that are more effective and less toxic than traditional chemotherapy.

Oxigene's product candidate, OXG-101, is a small molecule that selectively activates the mitochondrial apoptosis pathway, leading to cancer cell death. The company has reported positive results from Phase 1 and Phase 2 clinical trials of OXG-101 in patients with advanced pancreatic cancer. The Phase 3 trial is currently underway to confirm the safety and efficacy of OXG-101 in this patient population.

In addition to OXG-101, Oxigene is also developing other product candidates, including OXG-202 and OXG-301, which are in earlier stages of development.

Oxigene has received significant investment from major biotech investors, including a $75 million Series B funding round in 2020. The company has also received support from organizations such as the Pancreatic Cancer Action Network (PanCAN) and the National Cancer Institute (NCI).

Overall, Oxigene Inc. is a biotech company focused on developing innovative therapies for cancer treatment with their lead product candidate, OXG-101, in Phase 3 clinical trials.